The Nuremberg Code subverts human health and safety by requiring animal modeling

BMC Medical Ethics

Volumn 13, Issue 1, 2012, Pages

  Greek, Ray ^a   Pippus, Annalea ^a   Hansen, Lawrence A ^b  

^a Americans For Medical Advancement   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal; Biological complexity; Ethics; Evolution; Law; Nuremberg code; Species variation

Indexed keywords

ANIMAL; ANIMAL MODEL; BIOAVAILABILITY; DISEASE MODEL; ETHICS; FEMALE; FOOD AND DRUG ADMINISTRATION; GENETICS; HUMAN; HUMAN EXPERIMENT; INFORMED CONSENT; MALE; MEDICAL ETHICS; NONLINEAR SYSTEM; PREDICTIVE VALUE; PREGNANCY; RESEARCH ETHICS; RESEARCH SUBJECT; REVIEW; TOXICITY TESTING; UNITED STATES;

ANIMALS; BIOLOGICAL AVAILABILITY; CODES OF ETHICS; DISEASE MODELS, ANIMAL; ETHICS, RESEARCH; FEMALE; GENETICS; HELSINKI DECLARATION; HUMAN EXPERIMENTATION; HUMANS; INFORMED CONSENT; MALE; MODELS, ANIMAL; NONLINEAR DYNAMICS; PREDICTIVE VALUE OF TESTS; PREGNANCY; RESEARCH SUBJECTS; TOXICITY TESTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84863463591     PISSN: None     EISSN: 14726939     Source Type: Journal    
DOI: 10.1186/1472-6939-13-16     Document Type: Article

References (180)

1. Vivisection In Historical Perspective. edn. Maehle A-H, Trohler U, Animal Experimentation from Antiquity to the End of the Eighteenth Century: Attitudes and Arguments Croom Helm, London, Rupke N, 1987 14 47
2. Vivisection in Historical Perspective. edn. Elliot P, Vivisection and the Emergence of Experimental Medicine in Nineteenth Century France Croom Helm, New York, Rupke N, 1987 48 77
3. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Wax PM, Ann Intern Med 1995 122 6 456 461 7856995
4. Nuremberg Trial, United States v. Karl Brandt et al., "The Medical Case, Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10" U.S. Government Printing Office, Washington, D.C 1949
5. Taylor T, The Anatomy of the Nuremberg Trials: A Personal Memoir Knopf, New York 1992
6. Annas GJ, Grodin MA, The Nazi Doctors and the Nuremberg Code Oxford University Press, Inc., New York 1992
7. Harvard Law School Library, Nuremberg Trials Project. A Digital Document Collection Introduction to NMT Case 1, U.S.A. v. Karl Brandt et al [ http://nuremberg.law.harvard.edu/php/docs-swi.php?DI=1&text=medical-persons ]
8. American Medical Association, Board of Trustees. American Medical Association, Minutes of the May 1946 meeting, (ACHRE No. IND-072595-A), 156-157 AMA Archive, Chicago, Illinois 1946
9. Reassessing the Influence of the Nuremberg Code on American Medical Ethics. Moreno JD, Journal of Contemporary Health Law and Policy 1997 13 2 347 360 9212522
10. American Medical Association, Board of Trustees: 1946. American Medical Association, Minutes of the 19 September 1946 meeting, AMA Archive, Chicago, Illinois (ACHRE No. IND-072595-A), 51-52 AMA Archives, Chicago, IL 1946
11. Ivy AC, Report on War Crimes of a Medical Nature Committed in Germany and Elsewhere on German Nationals and the Nationals of Occupied Countries by the Nazi Regime during World War II," 1946. This report was not published, but it is available at the National Library of Medicine. A copy also exists in the AMA Archive (ACHRE No. DOD-063094-A) 1946
12. Chapter 2: The American Expert, the American Medical Association, and the Nuremburg Medical Trial [ http://www.hss.energy.gov/HealthSafety/ohre/roadmap/ achre/chap2-2.html ]
13. WMA Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects [ http://www.wma.net/en/30publications/10policies/b3/ ]
14. Bioethics and Animal Experimentation. LaFrance AB, Animal Law 1996 2 157
15. NIH, Regulations and Ethical Guidelines. Reprinted from Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10, Vol. 2 U.S. Government Printing Office, Washington, D.C 1949 181 182 [ http://ohsr.od.nih.gov/guidelines/nuremberg.html ]
16. The Law Pertaining to the Protection of Animals. JAMA 1934 102 7 551 552
17. New Regulations Concerning Vivisection. JAMA 1933 101 14 1087 1088
18. Animal experimentation in Nazi Germany. Fritzsche U, Hosp Pract (Off Ed) 1990 16 4A 18
19. Nazis and animal protection. Fritzsche U, Anthrozoös 1992 5 4 218 219
20. A darker shade of green: medical botany, homeopathy, and cultural politics in interwar Germany. Kenny MG, Soc Hist Med 2002 15 3 481 504 10.1093/shm/15.3.481 12659098
21. Promising Protection Through Internationally Derived Duties. Orlowski V, Cornell International Law Journal 2004 36 381
22. Food and Drugs Act (R.S.C., 1985, c. F-27) [ http://laws.justice.gc.ca/ eng/acts/F-27/page-7.html-h-12 ]
23. Food and Drug Regulations (C.R.C., c. 870) [ http://laws-lois.justice.gc. ca/eng/regulations/C.R.C.,-c.-870/page-296.html?term= regulations+drugs+food+drug-s-G.01.001 ]
24. Statutory Instruments Act (R.S.C., 1985, c. S-22) [ http://laws-lois. justice.gc.ca/eng/acts/S%2D22/ ]
25. Table IV: Number of Animals Used in 2009 by Participants in the CCAC Program according to Purpose of Animal Use and the Category of Invasiveness http://www.ccac.ca/en-/publications/audf/stats-aud/table-IV/2009 ]
26. International Conference on Harmonisation; Draft Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. US Food and Drug Administration, Fed Regist 73 ed. HHSs 51491 2 [ http://www.fda.gov/cder/guidance/8500dft.htm ]
27. Paul JR, A History of Poliomyelitis Yale University Press, New Haven 1971
28. Ehrlich P, Hata S, Die experimentalle Chemotherapie der Spirillosen Springer, Berlin 1910
29. What evolution Is. Mayr E, Basic Books 2002
30. Animal Experimentation: The Legacy of Claude Bernard. LaFollette H, Shanks N, Int Stud Philos Sci 1994 8 3 195 210 10.1080/02698599408573495
31. Bernard C, An Introduction to the Study of Experimental Medicine Dover, New York 1957 (1865)
32. Hemangioma in twins. Cheung DS, Warman ML, Mulliken JB, Ann Plast Surg 1997 38 3 269 274 10.1097/00000637-199703000-00014 9088466
33. Cancer research. Probing the roots of race and cancer. Couzin J, Science 2007 315 5812 592 594 10.1126/science.315.5812.592 17272699
34. Senile macular changes in the black African. Gregor Z, Joffe L, Br J Ophthalmol 1978 62 8 547 550 10.1136/bjo.62.8.547 687553
35. Ethnic and racial differences in the smoking-related risk of lung cancer. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, Le Marchand L, N Engl J Med 2006 354 4 333 342 10.1056/NEJMoa033250 16436765
36. Common genetic variants account for differences in gene expression among ethnic groups. Spielman RS, Bastone LA, Burdick JT, Morley M, Ewens WJ, Cheung VG, Nat Genet 2007 39 2 226 231 10.1038/ng1955 17206142
37. The pharmacogenetics of analgesia. Stamer UM, Stuber F, Expert Opin Pharmacother 2007 8 14 2235 2245 10.1517/14656566.8.14.2235 17927480
38. Genetics and variable drug response. Wilke RA, Dolan ME, JAMA: The Journal of the American Medical Association 2011 306 3 306 307 10.1001/jama.2011.998
39. Sex and the suffering brain. Holden C, Science 2005 308 5728 1574 10.1126/science.308.5728.1574 15947170
40. Gender in the pharmacy: does it matter? Kaiser J, Science 2005 308 5728 1572 10.1126/science.308.5728.1572 15947169
41. Wanted: women in clinical trials. Simon V, Science 2005 308 5728 1517 10.1126/science.1115616 15947140
42. Of Mice and Women: The Bias in Animal Models. Wald C, Wu C, Science 2010 327 5973 1571 1572 10.1126/science.327.5973.1571 20339045
43. HIV gender clues emerge. Willyard C, Nat Med 2009 15 8 830 19661977
44. Animal models in biomedical research: some epistemological worries. LaFollette H, Shanks N, Public Aff Q 1993 7 2 113 130 11652915
45. LaFollette H, Shanks N, Brute Science: Dilemmas of animal experimentation Routledge, London and New York 1996
46. Shanks N, Greek R, Animal Models in Light of Evolution Brown Walker, Boca Raton 2009
47. Are animal models predictive for humans? Shanks N, Greek R, Greek J, Philos Ethics Humanit Med 2009 4 1 2 10.1186/1747-5341-4-2 19146696
48. Is the use of sentient animals in basic research justifiable? Greek R, Greek J, Philos Ethics Humanit Med 2010 5 14 10.1186/1747-5341-5-14 20825676
49. The History and Implications of Testing Thalidomide on Animals. Greek R, Shanks N, Rice MJ, The Journal of Philosophy, Science & Law 2011 11
50. A gene complex controlling segmentation in Drosophila. Lewis EB, Nature 1978 276 5688 565 570 10.1038/276565a0 103000
51. Molecular cloning and chromosome mapping of a mouse DNA sequence homologous to homeotic genes of Drosophila. McGinnis W, Hart CP, Gehring WJ, Ruddle FH, Cell 1984 38 3 675 680 10.1016/0092-8674(84)90262-9 6091896
52. Shaping animal body plans in development and evolution by modulation of Hox expression patterns. Gellon G, McGinnis W, Bioessays 1998 20 2 116 125 10.1002/(SICI)1521-1878(199802)20:2<116::AID-BIES4>3.0.CO;2-R 9631657
53. The zootype and the phylotypic stage. Slack JM, Holland PW, Graham CF, Nature 1993 361 6412 490 492 10.1038/361490a0 8094230
54. A physical map of the human genome. McPherson JD, Marra M, Hillier L, Waterston RH, Chinwalla A, Wallis J, Sekhon M, Wylie K, Mardis ER, Wilson RK, et al. Nature 2001 409 6822 934 941 10.1038/35057157 11237014
55. The sequence of the human genome. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, et al. Science 2001 291 5507 1304 1351 10.1126/science.1058040 11181995
56. Evolution at two levels in humans and chimpanzees. King MC, Wilson AC, Science 1975 188 4184 107 116 10.1126/science.1090005 1090005
57. Predicting the clinical relevance of drug interactions from pre-approval studies. Caccia S, Garattini S, Pasina L, Nobili A, Drug Saf 2009 32 11 1017 1039 10.2165/11316630-000000000-00000 19810775
58. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Martignoni M, Groothuis GM, de Kanter R, Expert Opin Drug Metab Toxicol 2006 2 6 875 894 10.1517/17425255.2.6.875 17125407
59. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Donato MT, Castell JV, Clin Pharmacokinet 2003 42 2 153 178 10.2165/00003088-200342020-00004 12537515
60. Adjuvant Therapy with Trastuzumab for HER-2/neu-Positive Breast Cancer. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ, Oncologist 2006 11 8 857 867 10.1634/theoncologist.11-8-857 16951389
61. Hox cluster duplications and the opportunity for evolutionary novelties. Wagner GP, Amemiya C, Ruddle F, Proc Natl Acad Sci U S A 2003 100 25 14603 14606 10.1073/pnas.2536656100 14638945
62. Zebrafish hox clusters and vertebrate genome evolution. Amores A, Force A, Yan YL, Joly L, Amemiya C, Fritz A, Ho RK, Langeland J, Prince V, Wang YL, et al. Science 1998 282 5394 1711 1714 9831563
63. Hox, ParaHox, ProtoHox: facts and guesses. Garcia-Fernandez J, Heredity 2005 94 2 145 152 10.1038/sj.hdy.6800621 15578045
64. Paracelsus, Der Buecher und Schriften VII 1590 172
65. Reference Manual on Scientific Evidence. Goldstein BD, Henifin MS, Reference Guide on Toxicology National Academy of Sciences, Washington DC, Kassirer JP, Kessler G, Third Edition 2011 633 685
66. Pharmacogenetics and the practice of medicine. Roses AD, Nature 2000 405 6788 857 865 10.1038/35015728 10866212
67. Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Bruder CE, Piotrowski A, Gijsbers AA, Andersson R, Erickson S, de Stahl TD, Menzel U, Sandgren J, von Tell D, Poplawski A, et al. Am J Hum Genet 2008 82 3 763 771 10.1016/j.ajhg.2007.12.011 18304490
68. Epigenetic differences arise during the lifetime of monozygotic twins. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suner D, Cigudosa JC, Urioste M, Benitez J, et al. Proc Natl Acad Sci U S A 2005 102 30 10604 10609 10.1073/pnas.0500398102 16009939
69. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Javierre BM, Fernandez AF, Richter J, Al-Shahrour F, Martin-Subero JI, Rodriguez-Ubreva J, Berdasco M, Fraga MF, O'Hanlon TP, Rider LG, et al. Genome Res 2010 20 2 170 179 10.1101/gr.100289.109 20028698
70. Phenotypic differences in genetically identical organisms: the epigenetic perspective. Wong AH, Gottesman II, Petronis A, Hum Mol Genet 2005 14 1 11 18 10.1093/hmg/ddi116 15809262
71. Predictive tests and personalised medicine. Blair E, Drug Discovery World 2009 10 4 27 31
72. Big pharma moves from 'blockbusters' to 'niche busters'. Dolgin E, Nat Med 2010 16 8 837 837 20689537
73. Inhibition of mutated, activated BRAF in metastatic melanoma. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. N Engl J Med 2010 363 9 809 819 10.1056/NEJMoa1002011 20818844
74. Genomics, health care, and society. Hudson KL, N Engl J Med 2011 365 11 1033 1041 10.1056/NEJMra1010517 21916641
75. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Hughes AR, Spreen WR, Mosteller M, Warren LL, Lai EH, Brothers CH, Cox C, Nelsen AJ, Hughes S, Thorborn DE, et al. Pharmacogenomics J 2008 8 6 365 374 10.1038/tpj.2008.3 18332899
76. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H, Guerrieri-Gonzaga A, Plebani M, Basso D, Gjerde J, et al. Pharmacogenomics J 2011 11 2 100 107 10.1038/tpj.2010.17 20309015
77. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W, Pharmacogenomics J 2011 11 4 274 86 10.1038/tpj.2010.28 20386561
78. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Lyman GH, Cosler LE, Kuderer NM, Hornberger J, Cancer 2007 109 6 1011 1018 10.1002/cncr.22506 17311307
79. Melanoma-an unlikely poster child for personalized cancer therapy. Smalley KS, Sondak VK, N Engl J Med 2010 363 9 876 878 10.1056/NEJMe1005370 20818849
80. Cancer Treatments get Personal. Thomas H, New Scientist 2009 2704 48 50
81. Creating and evaluating genetic tests predictive of drug response. Weiss ST, McLeod HL, Flockhart DA, Dolan ME, Benowitz NL, Johnson JA, Ratain MJ, Giacomini KM, Nat Rev Drug Discov 2008 7 7 568 574 10.1038/nrd2520 18587383
82. Animal Models in Toxicology. Gad S, Preface CRC Press, Boca Rotan, Gad S, 2007 1 18
83. Handbook of Laboratory Animal Science Second Edition Animal Models. Volume II. Hau J, Animal Models CRC Press, Boca Rotan, Hau J, Hoosier GK Jr, 2 2003 1 9
84. Longer Tests on Lab Animals Urged for Potential Carcinogens [ http://www.cspinet.org/new/200811172.html ]
85. The limits of two-year bioassay exposure regimens for identifying chemical carcinogens. Huff J, Jacobson MF, Davis DL, Environ Health Perspect 2008 116 11 1439 1442 10.1289/ehp.10716 19057693
86. Symposium on clinical drug evaluation and human pharmacology. XVI. Evaluation of the safety of new drugs by means of tests in animals. Litchfield JT Jr, Clin Pharmacol Ther 1962 3 665 672 14465857
87. The cardio-toxicity of isoprenaline during hypoxia. Collins JM, McDevitt DG, Shanks RG, Swanton JG, Br J Pharmacol 1969 36 1 35 45 10.1111/j.1476-5381. 1969.tb08301.x 5768127
88. Inman WH, Monitoring for Drug Safety 1980
89. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Stolley PD, Am Rev Respir Dis 1972 105 6 883 890 5032708
90. Fatal asthma. Stolley PD, Schinnar R, Lancet 1979 2 8148 897 90980
91. Studies in Cardiac Necrosis. 3. Metabolic Effects of Sympathomimetic Amines Producing Cardiac Lesions. Rosenblum I, Wohl A, Stein AA, Toxicol Appl Pharmacol 1965 7 344 351 10.1016/0041-008X(65)90103-1 14298025
92. Studies in Cardiac Necrosis. Ii. Cardiovascular Effects of Sympathomimetic Amines Producing Cardiac Lesions. Rosenblum I, Wohl A, Stein AA, Toxicol Appl Pharmacol 1965 7 9 17 10.1016/0041-008X(65)90068-2 14256610
93. Studies in Cardiac Necrosis. I. Production of Cardiac Lesions with Sympathomimetic Amines. Rosenblum I, Wohl A, Stein AA, Toxicol Appl Pharmacol 1965 7 1 8 14256598
94. Drug safety tests and subsequent clinical experience. Fletcher AP, J R Soc Med 1978 71 9 693 696 712750
95. Target organ toxicity. Heywood R, Toxicol Lett 1981 8 6 349 358 10.1016/0378-4274(81)90125-9 7302965
96. Target organ toxicity II. Heywood R, Toxicol Lett 1983 18 1-2 83 88 6623552
97. The lifetime feeding study in mice and rats-an examination of its validity as a bioassay for human carcinogens. Salsburg D, Fundam Appl Toxicol 1983 3 1 63 67 10.1016/S0272-0590(83)80174-2 6884625
98. Toxic effects of chemicals: difficulties in extrapolating data from animals to man. Garattini S, Crit Rev Toxicol 1985 16 1 1 29 10.3109/10408448509041323 3910353
99. Animal Toxicity Studies: Their Relevance for Man. Heywood R, Clinical Toxicity - Could it have been predicted? Post-marketing experience Quay, Lancaster, Lumley CE, Walker S, 1990 57 67
100. Concordance of the toxicity of pharmaceuticals in humans and in animals. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, et al. Regul Toxicol Pharmacol 2000 32 1 56 67 10.1006/rtph.2000.1399 11029269
101. Animal Toxicity Studies: Their Relevance for Man. Suter K, What can be learned from case studies? The company approach Quay, Lancaster, Lumley C, Walker S, 1990 71 78
102. Animal Toxicity Studies: Their Relevance for Man. Lumley C, Clinical toxicity: could it have been predicted? Premarketing experience Quay, London, Lumley C, Walker S, 1990 49 56
103. Spriet-Pourra C, Auriche M, SCRIP Reports PJB 1994
104. The importance of pharmacokinetic and receptor studies in drug safety evaluation. Eason CT, Bonner FW, Parke DV, Regul Toxicol Pharmacol 1990 11 3 288 307 10.1016/0273-2300(90)90028-A 2196638
105. CMR Workshop: The Timing of Toxicological Studies to Support Clinical Trials. Igarashi T, The duration of toxicity studies required to support repeated dosing in clinical investigation-A toxicologists opinion Kluwer, Boston/UK, Parkinson NM C, Lumley C, Walker SR, 1994 67 74
106. Predictability of clinical adverse reactions of drugs by general pharmacology studies. Igarashi T, Nakane S, Kitagawa T, J Toxicol Sci 1995 20 2 77 92 10.2131/jts.20.77 7473897
107. Study design and statistical analysis of toxicokinetics: a report of JPMA investigation of case studies. Igarashi T, Yabe T, Noda K, J Toxicol Sci 1996 21 5 497 504 10.2131/jts.21.5-497 9035061
108. Detection of systemic hypersensitivity to drugs using standard guinea pig assays. Weaver JL, Staten D, Swann J, Armstrong G, Bates M, Hastings KL, Toxicology 2003 193 3 203 217 10.1016/S0300-483X(03)00267-1 14599760
109. The Virtual Patient. Willis RC, Modern Drug Discovery 2003 6 2 35 40
110. The Delicate Toxicity Balance in Drug Discovery. Sankar U, Scientist 2005 19 15 32
111. Species similarities and differences in pharmacokinetics. Lin JH, Drug Metab Dispos 1995 23 10 1008 1021 8654187
112. Overview of the Final MEIC Results:II. The In Vitro - In Vivo Evaluation, Including the Selection of a Practical Battery of Cell Tests for Prediction of Acute Lethal Blood Concentrations in Humans. Ekwall B, Toxicol In Vitro 1999 13 4-5 665 673 20654532
113. Eye irritation responses in rabbit and man after single applications of equal volumes of undiluted model liquid detergent products. Roggeband R, York M, Pericoi M, Braun W, Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 2000 38 8 727 734 10.1016/S0278-6915(00)00057-0
114. An urgent need to restrict access to pesticides based on human lethality. Miller M, Bhalla K, PLoS Med 2010 7 10 1000358 10.1371/journal.pmed.1000358 21048989
115. Acute human lethal toxicity of agricultural pesticides: a prospective cohort study. Dawson AH, Eddleston M, Senarathna L, Mohamed F, Gawarammana I, Bowe SJ, Manuweera G, Buckley NA, PLoS Med 2010 7 10 1000357 10.1371/journal.pmed.1000357 21048990
116. The absolute oral bioavailability of selected drugs. Sietsema WK, Int J Clin Pharmacol Ther Toxicol 1989 27 4 179 211 2654032
117. Foundation review: Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition. Giri S, Bader A, Drug Discovery Today 2011 16 9/10 382 397 21354326
118. Predictive chemoinformatics: applications to the pharmaceutical industry. Browne LJ, Taylor LL, Drug Discovery World 2002 71 77 Fall
119. Cancer Models: Systems for identifying new drugs are often faulty. Gura T, Science 1997 278 5340 1041 1042 10.1126/science.278.5340.1041 9381203
120. Genomics and drug response. Wang L, McLeod HL, Weinshilboum RM, N Engl J Med 2011 364 12 1144 1153 10.1056/NEJMra1010600 21428770
121. Mann R, Andrews E, Pharmacovigilance John Wiley and Sons, Chichester 2 2006
122. Idiosyncratic drug hepatotoxicity. Kaplowitz N, Nat Rev Drug Discov 2005 4 6 489 499 10.1038/nrd1750 15931258
123. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A, Chem Res Toxicol 2010 23 1 171 183 10.1021/tx900326k 20014752
124. Species differences and the clinical trial of new drugs: a review. Koppanyi T, Avery MA, Clin Pharmacol Ther 1966 7 2 250 270 5327179
125. Inter-species differences in drug properties. Collins JM, Chem Biol Interact 2001 134 3 237 242 10.1016/S0009-2797(01)00158-2 11336972
126. Animal carcinogenicity studies: 1. Poor human predictivity. Knight A, Bailey J, Balcombe J, Altern Lab Anim 2006 34 1 19 27 16522147
127. The rat as a model for human toxicological evaluation. Oser BL, J Toxicol Environ Health 1981 8 4 521 542 10.1080/15287398109530089 7338928
128. Suitability of animal models for predictive toxicology: theoretical and practical considerations. Calabrese EJ, Drug Metab Rev 1984 15 3 505 523 10.3109/03602538409029971 6435984
129. Calabrese EJ, Principles of Animal Extrapolation CRC Press, Boca Rotan 1991
130. Comparison of treatment effects between animal experiments and clinical trials: systematic review. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS, BMJ 2007 334 7586 197 10.1136/bmj.39048.407928.BE 17175568
131. Testing Treatment on Animals: Relevance to Humans [ http://www.pcpoh. bham.ac.uk/publichealth/methodology/docs/invitations/JH18-Final-Report-April- 2006.pdf ]
132. [Animal experiments in biomedical research. An evaluation of the clinical relevance of approved animal experimental projects]. Lindl T, Voelkel M, Kolar R, ALTEX 2005 22 3 143 151 16186990
133. Animal experiments in biomedical research. An evaluation of the clinical relevance of approved animal experimental projects: No evident implementation in human medicine within more than 10 years. [Lecture abstract.]. Lindl T, Völkel M, Kolar R, ALTEX 2006 23 111
134. The liver and lovastatin. Tolman KG, Am J Cardiol 2002 89 12 1374 1380 10.1016/S0002-9149(02)02355-X 12062731
135. Drug-related hepatotoxicity. Navarro VJ, Senior JR, N Engl J Med 2006 354 7 731 739 10.1056/NEJMra052270 16481640
136. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Dixit R, Boelsterli U, Drug Discovery Today 2007 12 7-8 336 342 17395094
137. Toxicity Testing in the 21st Century [ http://www.alttox.org/ttrc/ overarching-challenges/way-forward/andersen/ ]
138. Toxicology for the twenty-first century. Hartung T, Nature 2009 460 7252 208 212 10.1038/460208a 19587762
139. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Force T, Kolaja KL, Nat Rev Drug Discov 2011 10 2 111 126 10.1038/nrd3252 21283106
140. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N, N Engl J Med 2006 355 10 1018 1028 10.1056/NEJMoa063842 16908486
141. Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412. Dayan CM, Wraith DC, Clin Exp Immunol 2008 151 2 231 234 10.1111/j.1365-2249.2007.03559.x 18190459
142. Addressing the Ethical Challenges of First-in-Human Trials. Chapman AR, J Clinic Res Bioeth 2011 2 4 113
143. Gene therapy on trial. Marshall E, Science 2000 288 5468 951 957 10.1126/science.288.5468.951 10841710
144. Risks and benefits of phase 1 oncology trials, 1991 through 2002. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, Shoemaker D, Emanuel EJ, Grady C, N Engl J Med 2005 352 9 895 904 10.1056/NEJMsa042220 15745980
145. How can institutional review boards best interpret preclinical data? Lavery JV, PLoS medicine 2011 8 3 1001011 10.1371/journal.pmed.1001011 21423343
146. Extending Clinical Equipoise to Phase I Trials Involving Patients: Unresolved Problems. Anderson J, Kimmelman J, Kennedy Inst Ethics J 2010 20 79 81
147. Defining the role of pharmacology in the emerging world of translational research. Enna SJ, Williams M, Adv Pharmacol 2009 57 1 30 20230758
148. Transgenic and gene-targeted mice as models for chronic obstructive pulmonary disease. Shapiro SD, Eur Respir J 2007 29 2 375 378 17264324
149. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Rangarajan A, Weinberg RA, Nat Rev Cancer 2003 3 12 952 959 10.1038/nrc1235 14737125
150. Why we are losing the war on cancer. Leaf C, Fortune 2004 77 92 March 9
151. Greek R, Shanks N, FAQs About the Use of Animals in Science: A handbook for the scientifically perplexed University Press of America, Lanham 2009
152. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Lappin G, Garner RC, Nat Rev Drug Discov 2003 2 3 233 240 10.1038/nrd1037 12612650
153. The utility of microdosing over the past 5 years. Lappin G, Garner RC, Expert Opinion on Drug Metabolism & Toxicology 2008 4 12 1499 1506 10.1517/17425250802531767 23153186
154. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC, Clin Pharmacol Ther 2006 80 3 203 215 10.1016/j.clpt.2006.05.008 16952487
155. Abadie R, The Professional Guinea Pig: Big Pharma and the Risky World of Human Subjects Duke University Press Books, Durham 2010
156. The institutional review board is an impediment to human research: the result is more animal-based research. Rice MJ, Philosophy, ethics, and humanities in medicine: PEHM 2011 6 12 10.1186/1747-5341-6-12 21649895
157. Funding for practice-oriented clinical research. Rothwell PM, Lancet 2006 368 9532 262 266 10.1016/S0140-6736(06)69010-7 16860680
158. Scientific Achievements Less Prominent Than a Decade Ago. Public praises science; scientists fault public, media [ http://people-press.org/report/528/ ]
159. Let the people speak. Aldhous P, Coghlan A, Copley J, New Scientist 1999 2187 May 22
160. Special Eurobarometer: Social values, Science and Technology [ http://ec.europa.eu/public-opinion/archives/ebs/ebs-225-report-en.pdf ]
161. Four Moral Issues Sharply Divide Americans [ http://www.gallup.com/poll/ 137357/Four-Moral-Issues-Sharply-Divide-Americans.aspx?utm-source= alert&utm-medium=email&utm-campaign=syndication&utm-content= morelink&utm-term=Moral Issues ]
162. Animal experiments under fire for poor design. Giles J, Nature 2006 444 7122 981 10.1038/444981a 17183281
163. U.S. Investment In Health Research 2009 [ http://www.researchamerica.org/ uploads/healthdollar09.pdf ]
164. Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. Ioannidis JPA, JAMA: The Journal of the American Medical Association 2005 294 2 218 228 10.1001/jama.294.2.218
165. Translation of basic research into useful treatments: how often does it occur? Crowley WF Jr, Am J Med 2003 114 6 503 505 10.1016/S0002-9343(03)00119-0 12727585
166. Daubert v. Merrell Dow Pharms., 509 U.S. 579, 584 (U.S., 1993) In
167. Viterbo v. Dow Chemical Co., 826 F.2d 420 (5th Cir. 1987) In
168. Selwood v. Oxford Chemicals, Inc., No. 90-1048 (M.D. Pa. June 28, 1991) In
169. Joiner v. General Elec. Co., 864 F. Supp. 1310, 1323 (N.D. Ga. 1994) In
170. Bourne v. E.I.DuPont de Nemours and Company, 189 F Supp. 2d 482 (S.D. W.Va. 2002)
171. Biological spectra analysis: Linking biological activity profiles to molecular structure. Fliri AF, Loging WT, Thadeio PF, Volkmann RA, Proc Natl Acad Sci U S A 2005 102 2 261 266 10.1073/pnas.0407790101 15625110
172. Drugs by Design. Borman S, Chemical & Engineering News 2005 28 23166964
173. Models Predict Toxicity of Compounds, [ http://www.dddmag.com/product- Models-Predict-Toxicity-of-Compounds-052611.aspx?et-cid=1799359&et-rid= 45518461&linkid=http%3a%2f%2fwww.dddmag.com%2fproduct-Models-Predict- Toxicity-of-Compounds-052611.aspx ]
174. Characterization and culture of human embryonic stem cells. Hoffman LM, Carpenter MK, Nat Biotechnol 2005 23 6 699 708 10.1038/nbt1102 15940242
175. Cell biology. Human embryonic stem cells may be toxicology's new best friends. Sinha G, Science 2005 308 5728 1538 10.1126/science.308.5728.1538 15947151
176. Of mice and men: bridging the translational disconnect in CNS drug discovery. Geerts H, CNS Drugs 2009 23 11 915 926 10.2165/11310890-000000000- 00000 19845413
177. Altman L, Who Goes First? The Story of Self-Experimentation in Medicine University of California Press 1998
178. What Will We Do if We Don't Experiment on Animals? Greek J, Greek R, Trafford 2004
179. The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. Regenberg A, Mathews DJ, Blass DM, Bok H, Coyle JT, Duggan P, Faden R, Finkel J, Gearhart JD, Hillis A, et al. J Cereb Blood Flow Metab 2009 29 1 1 9 10.1038/jcbfm.2008.98 18728679
180. The ultimate model organism: progress in experimental medicine. Littman BH, Williams SA, Nat Rev Drug Discov 2005 4 8 631 638 10.1038/nrd1800 16056389